Holen Sie sich die Stockscreener-App
1.55
1.25%
-0.05
Handel nachbörslich:
1.56
0.01
+0.65%
Schlusskurs vom Vortag:
$1.60
Offen:
$1.6
24-Stunden-Volumen:
3,328
Relative Volume:
0.14
Marktkapitalisierung:
$2.56M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-36.46M
KGV:
-0.6458
EPS:
-2.4
Netto-Cashflow:
$-30.20M
1W Leistung:
-5.95%
1M Leistung:
-4.53%
6M Leistung:
-42.96%
1J Leistung:
-93.28%
1-Tages-Spanne:
$1.55
$1.615
1-Wochen-Bereich:
$1.57
$1.68
52-Wochen-Spanne:
$1.50
$23.20
Alaunos Therapeutics Inc Stock (TCRT) Company Profile
Firmenname
Alaunos Therapeutics Inc
Sektor
Branche
Telefon
(346) 355-4099
Adresse
2617 BISSONNET ST, HOUSTON
Vergleichen Sie TCRT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TCRT
Alaunos Therapeutics Inc
|
1.55 | 2.56M | 0 | -36.46M | -30.20M | -2.40 |
|
VRTX
Vertex Pharmaceuticals Inc
|
479.79 | 121.85B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
698.74 | 76.83B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
624.67 | 37.96B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.75 | 30.69B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beone Medicines Ltd Adr
|
271.80 | 29.71B | 3.32B | -860.46M | -1.04B | -8.32 |
Alaunos Therapeutics Inc Stock (TCRT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-10-04 | Fortgesetzt | Wells Fargo | Overweight |
Alaunos Therapeutics Inc Aktie (TCRT) Neueste Nachrichten
Lantheus acquires radiopharma CDMO Evergreen for up to $1bn - Pharmaceutical Technology
Alaunos Therapeutics (NASDAQ:TCRT) Stock Price Up 4% – Should You Buy? - Defense World
Alaunos Therapeutics (NASDAQ:TCRT) Stock Price Down 0.5% – Time to Sell? - Defense World
TCRT stock touches 52-week low at $1.92 amid market challenges - Investing.com
Novartis acquires Kate Therapeutics to advance gene therapies - Pharmaceutical Technology
Alaunos Therapeutics Inc (TCRT) Quarterly 10-Q Report - Quartzy
Ziopharm: Q3 Earnings Snapshot - The Washington Post
TCRT Stock Touches 52-Week Low at $1.96 Amid Market Challenges - Investing.com Nigeria
TCRT stock touches 52-week low at $2.06 amid market challenges - Investing.com
Intracranial Therapeutic Market Rewriting its Growth Cycle |Novartis AG, BioMarin, CORESTEM Inc., Alaunos Therapeutics, – IndiaPolitics.com - IndiaPolitics.com
After axing its sole clinical prospect last year, Alaunos cuts ties with Precigen - Fierce Biotech
Alaunos Therapeutics ends key agreement and updates on financial condition By Investing.com - Investing.com Australia
Alaunos Therapeutics Ends Licensing Deal, Reassesses Strategy - Yahoo Finance
Precigen reclaims rights after terminating license agreement - Investing.com India
Precigen Terminates License Agreement With Alaunos Therapeutics - MarketWatch
Alaunos Therapeutics ends key agreement and updates on financial condition - Investing.com
Genentech buys Regor’s CDK inhibitors in $850m deal - Clinical Trials Arena
AskBio and Belief BioMed partner to advance gene therapies - Pharmaceutical Technology
Applied Therapeutics: AdCom Decision Takes Govorestat Approval A Step Closer (NASDAQ:APLT) - Seeking Alpha
An Analysis of Atricure Inc (ATRC)’s Potential Price Growth - Knox Daily
Applied Therapeutics Surges on Positive FDA Update for Govorestat - BP Journal
Applied Therapeutics jumps as US FDA cancels panel meeting for genetic disorder drug - XM
Gene Switch / Molecular Switch Market Set to Reach USD 1.44 Billion by 2031 with 9.9% CAGR - WhaTech
Daily Market Movement: Atricure Inc (ATRC) Sees a -3.23 Decrease, Closing at 27.30 - The Dwinnex
Aptevo Therapeutics announces $3.0M offering priced at-the-market - TipRanks
Check out these key findings about Atricure Inc (ATRC) - SETE News
Atmos Energy Co. (NYSE:ATO) Shares Sold by Prudential PLC - MarketBeat
Gilead and Genesis partner to create novel therapies using AI - Pharmaceutical Technology
Navigator gains $100m in Series A funding for antibody therapeutics - Pharmaceutical Technology
VION Biosciences acquires Echelon Biosciences - Pharmaceutical Technology
TCRT stock touches 52-week low at $2.28 amid market challenges - Investing.com India
Ziopharm: Q2 Earnings Snapshot - Weatherford Democrat
Eli Lilly inaugurates R&D facility in Boston, US - Pharmaceutical Technology
Genentech and Sangamo to develop neurodegenerative disease therapies - Pharmaceutical Technology
Alaunos Therapeutics announces 1-for-10 reverse stock split By Investing.com - Investing.com Australia
Alaunos Therapeutics announces 1-for-10 reverse stock split - Investing.com
XyloCor taps SmartWise’s infusion device for gene therapy administration - Clinical Trials Arena
Turn Bio and HanAll to develop therapies for age-related conditions - Pharmaceutical Technology
Avenzo Therapeutics secures $150m to bolster oncology pipeline - Pharmaceutical Technology
Gilead concludes acquisition of CymaBay Therapeutics for $4.3bn - Pharmaceutical Technology
Why C.H. Robinson Shares Are Trading Lower By Over 12%? Here Are Other Stocks Moving In Thursday's Mid-Day Session - Markets Insider
Alaunos Therapeutics Announces 1-for-15 Reverse Stock Split - TipRanks
TScan Therapeutics Appoints Jason A. Amello as Chief Financial Officer - citybiz
Kyowa Kirin acquires Orchard Therapeutics for $477.6m - Pharmaceutical Technology
NAYA buys gene therapy company Florida Biotech for $20m - Pharmaceutical Technology
Genentech signs nanoparticle deal worth up to $644m with GenEdit - Pharmaceutical Technology
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday - InvestorPlace
Avistone raises $140m to support drug research and development - Pharmaceutical Technology
BridGene and Galapagos partner for oncology drugs discovery - Pharmaceutical Technology
Novartis allies with Voyager to develop gene therapies in $1.3bn deal - Pharmaceutical Technology
Why Is Alaunos Therapeutics (TCRT) Stock Up 37% Today? - MSN
Finanzdaten der Alaunos Therapeutics Inc-Aktie (TCRT)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.95%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):